Sanofi and Verily Launch Onduo

News
Article

The companies launched Onduo, a joint venture focused on developing solutions to assist patients with Type 2 diabetes.

On Sept. 12, 2016 Sanofi and Verily Life Sciences announced the launch of Onduo, a joint venture created through Sanofi and Verily’s diabetes-focused collaboration. Onduo is designed to help patients with diabetes through the development of solutions that combine devices, software, medicine, and professional care. The companies appointed Joshua Riff, MD, MBA, Onduo’s chief executive officer, a former senior vice-president of UnitedHealth Group. “We want to develop solutions that allow people living with diabetes to focus on the things they love and enjoy in life by providing tools to make dealing with their diabetes less burdensome,” Riff said in a statement.

Onduo will initially focus on Type 2 diabetes, specifically focusing on improved medication management, and other daily decisions to help patients better manage their diabetes. Eventually Onduo says it will expand to include Type 1 diabetes and eventually, to people at risk of developing diabetes. Sutter Health of Northern California and Allegheny Health Network of western Pennsylvania are among the first healthcare networks to collaborate with Verily and Onduo to test the Onduo platform with healthcare professionals and people with Type 2 diabetes in a clinical-care setting.

Source: Sanofi

 

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Related Content